Journal
RESPIRATORY RESEARCH
Volume 18, Issue -, Pages -Publisher
BIOMED CENTRAL LTD
DOI: 10.1186/s12931-017-0559-0
Keywords
Eosinophils; COPD; Asthma COPD overlap; ACOS
Categories
Funding
- Almirall
- AstraZeneca
- Boehringer Ingelheim
- Chiesi
- Genentech
- GlaxoSmithKline
- Glenmark
- Merck
- NAPP
- Novartis
- Pfizer
- Skyepharma
- Takeda
- Teva
- Therevance
- Verona
Ask authors/readers for more resources
Eosinophilic COPD appears to be a distinct patient subgroup with an increased corticosteroid response. Eosinophilic COPD has been labelled as part of the asthma COPD overlap syndrome (ACOS). We compared the clinical characteristics of eosinophilic COPD patients (without any clinical history of asthma) and COPD patients with a childhood history of asthma. COPD patients with asthma were characterised by more allergies and more exacerbations, but less eosinophilic inflammation. While terms such as ACOS are used to lump patients together, we report distinct differences between eosinophilic COPD and COPD patients with asthma, and propose that these groups should be split rather than lumped.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available